cilomilast has been researched along with oleic acid in 1 studies
| Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) | Studies (oleic acid) | Trials (oleic acid) | Recent Studies (post-2010) (oleic acid) |
|---|---|---|---|---|---|
| 162 | 13 | 42 | 8,768 | 248 | 3,051 |
| Protein | Taxonomy | cilomilast (IC50) | oleic acid (IC50) |
|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 6.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alalaiwe, A; Elzoghby, AO; Fang, JY; Hsu, CY; Hwang, TL; Lin, CY | 1 |
1 other study(ies) available for cilomilast and oleic acid
| Article | Year |
|---|---|
Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug Carriers; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neutrophil Activation; Neutrophils; Nitriles; Oleic Acid; Phosphodiesterase 4 Inhibitors; Psoriasis | 2019 |